Inhibrx Biosciences, Inc.

Our team is attending #ICHNO2026 in Seville, Spain, joining the global oncology community to advance research on #HeadAndNeckCancers. Learn more about our ongoing research investigating INBRX-106 in head and neck cancer: tinyurl.com/j2he79ns

Learn more about our advancing research in #sarcoma: tinyurl.com/ycke3ybs

Our team is in Lugano for the #ESMORareCancers26! We are excited to share our updated data from our ozekibart (#INBRX109) program in #EwingSarcoma, which was presented by Dr. Ana Sebio as part of the scientific program.

Inhibrx will present updated data from our ozekibart (#INBRX109) program in #EwingSarcoma at the #ESMORareCancers26 in Lugano. The oral presentation will take place on March 12. Learn more about our research efforts in Ewing sarcoma and chondrosarcoma: tinyurl.com/ycke3ybs

Inhibrx continues to evaluate the use of ozekibart (#INBRX109) in #ColorectalCancer in our ongoing clinical program. Learn more: tinyurl.com/4tps55yt

March is #ColorectalCancerAwarenessMonth, a time dedicated to raising awareness, promoting early detection, and recognizing the importance of continued research in #ColorectalCancer.

Learn more about our research efforts in #EwingSarcoma and #chondrosarcoma: tinyurl.com/ycke3ybs

This #RareDiseaseDay, we honor the resilient rare oncology community by highlighting our ongoing research in Ewing sarcoma and chondrosarcoma through our ozekibart (INBRX-109) program.

World Rare Disease Day shines a light on the global rare disease community and the challenges patients and families face every day.

Today we encored results from ChonDRAgon, the Phase 2 study evaluating ozekibart (#INBRX109) in conventional #chondrosarcoma, at the 2026 @TheBSG_UK Annual Conference in Oxford. Learn more here: britishsarcomagroup.org.uk/events/event/b…

Learn more about our ongoing research efforts in #EwingSarcoma with our ozekibart (#INBRX109) program: tinyurl.com/4vt9bnpu

Among the many childhood cancers, #EwingSarcoma is one of the rare cancers that primarily affects younger populations and remains an area with a high unmet medical need.

#InternationalChildhoodCancerDay is an opportunity to raise awareness, show support for children and adolescents fighting cancer, and highlight the unmet need for continued research.

Inhibrx will continue its support of the @sarcomapatients as a Sustaining Partner. SPAGN brings together #sarcoma patient advocates, clinicians, and researchers from around the world to strengthen education, collaboration, and the patient voice across the sarcoma community.

Learn more about research efforts in conventional #chondrosarcoma: tinyurl.com/y6ctvnec #INBRX109 #ClinicalTrial

Chondrosarcoma Awareness Day is a time to recognize those impacted by this rare bone cancer and the work that continues across research and advocacy. Our team wore yellow in support of the chondrosarcoma community and to help raise awareness.

This #WorldCancerDay, we recognize the global impact of cancer and the importance of continued research across the scientific community. We remain focused on the work that lies ahead. #Biotech

Onyx recently featured an interview with Inhibrx Founder and CEO Mark Lappe on building a lean biotech model driven by focused teams and biology-first thinking. Read the full article: onyxnewsroom.com/mark-lappes-le…

A Phase 1 study evaluating #ozekibart (INBRX-109) is actively enrolling patients with Ewing sarcoma. Learn more about study details and enrollment: tinyurl.com/4vt9bnpu #INBRX109 #ewingsarcoma #ClinicalTrials

On behalf of everyone at Inhibrx, we wish you a wonderful holiday season.

The team at Inhibrx kicked off the holiday season with our annual Holiday Cookie Exchange. The event showcased the creativity and warmth of our incredible team as we shared homemade treats and made meaningful holiday memories.